Abstract. The 21-gene recurrence score (RS) predicts the prognosis of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer and the effectiveness of adding adjuvant chemotherapy on the basis of endocrine therapy to avoid excessive chemotherapy. The present study aimed to analyze clinicopathological characteristics and chemotherapeutic efficacy-related target genes with the 21-gene RS in hormone receptor-positive early-stage breast cancer in China. The prognostic value of chemotherapeutic efficacy-related target genes was also examined. In addition, this study investigated the postoperative adjuvant therapeutic decision-oriented role of 21-gene RS in hormone receptor-positive and lymph node-negative early-stage breast cancer. In the present retrospective study, 110 ER + /HER2 -early-stage breast cancer patients were tested with the 21-gene RS. The analyses of clinicopathological characteristics and chemotherapeutic efficacy-related target genes with the 21-gene RS were performed using the χ 2 test, the Wilcoxon rank-sum test and binary logistic regression. Kaplan-Meier survival plots were drawn in www.kmplot.com. Furthermore, the McNemar χ 2 test was used to compare the changes of treatment decisions before and after the 21-gene test. The median RS of 110 patients was 16 (range, 2-47), and patients were categorized as low (59.1%), intermediate (34.5%) or high risk (6.4%). The results revealed that higher body mass index, invasive ductal carcinoma type, higher histological grade, luminal B molecular type and higher thymidylate synthetase (TYMS) and DNA topoisomerase IIα (TOP2A) gene expression levels were more likely to have a higher RS. Kaplan-Meier plots suggested that expression of TYMS, tubulin β3 class III (TUBB3) and TOP2A genes was significantly associated with relapse-free survival for ER + breast cancer. Additionally, prior to 21-gene RS testing, 61 patients (55%) were recommended adjuvant chemotherapy and endocrine therapy; however, following 21-gene test, 32 patients (29%) were treated with only adjuvant endocrine therapy. TYMS, TUBB3 and TOP2A gene expression may have prognostic value for ER + breast cancer. In addition, 21-gene RS testing may aid to avoid excessive postoperative adjuvant chemotherapy.
Introduction
As the most prevalent cancer in women, breast cancer affects >1 million women worldwide and accounts for ~23% of all cases of cancer among women (1, 2) . In addition, the annual incidence of breast cancer in China was ~20,8000 cases in 2010, which accounted for 16 .2% of all cancer cases in females (3) . Breast cancer has become one of the main causes of death among young women in China (4). A multidisciplinary comprehensive treatment model has gradually been developed, including surgery, radiotherapy, chemotherapy and endocrine therapy (5) . These treatments have improved the long-term survival of patients with breast cancer and reduced the rates of recurrence and metastasis (6) . Nevertheless, chemotherapy has several side effects, and whether patients with low-risk early-stage breast cancer benefit from chemotherapy remains to be determined. Effective methods to accurately predict recurrence risk and simultaneously provide appropriate treatment to patients have not been established.
With the development of genomics (7), the treatment of breast cancer has stepped into a new era. The 21-gene recurrence score (RS) assay for patients with estrogen receptor (ER)-positive breast cancer has been demonstrated to be more accurate than clinicopathological indicators in predicting prognosis and metastasis (8) (9) (10) (11) . The 21-gene assay has already been recommended by the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology for patients with early-stage breast cancer (12, 13) . Based on the results of National Surgical Adjuvant Breast and Bowel Project (NSABP) B-20 trials, a score <18 was categorized as low risk, a score between 18 and 30 was considered intermediate risk and a score ≥31 was categorized as high risk (8, 14, 15) . This test helps screen out patients with low recurrence risk, thereby avoiding excessive chemotherapy. In a previous study, 70 surgeons at the Israeli Cancer clinics
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selected 300 Israeli patients with breast cancer to perform 21-gene RS tests (16) . The results demonstrated that age and tumor size had no correlation with the RS value. In addition, the NSABP B-20 and Southwest Oncology Group-8814 trials revealed that the RS predicted benefit from adjuvant chemotherapy in tumor-node-metastasis (TNM) node stage (N)0-3 patients (14, 17) . The 21-gene RS detection was obtained from large datasets abroad, but lacked the validation of large samples in China. In addition, the clinicopathological characteristics included in previous studies were limited. To the best of our knowledge, there have been no studies regarding the relationship between RS assay and chemotherapeutic efficacy-related target genes. Therefore, the present study aimed to analyze clinicopathological characteristics and chemotherapeutic efficacy-related target genes with 21-gene RS in patients with hormone receptor-positive early-stage breast cancer in China. The changes of treatment decisions before and after the 21-gene RS test were compared, and the prognostic value of chemotherapeutic efficacy-related target genes was examined to aid in the evaluation of the guiding significance of the 21-gene RS in the diagnosis and treatment of patients with breast cancer in China and to aid in the discovery of new prognostic markers.
Materials and methods

Data and patients.
A retrospective, single-center study was conducted at The First Affiliated Hospital of Xi'an Jiaotong University (Xi'an, China). The data from 110 patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative T1-3N0M0 breast cancer who were tested for the 21-gene RS and underwent surgical treatment between June 2013 and December 2016 were reviewed. Exclusion criteria were patients with T4 tumors, those having received neoadjuvant therapy or those with distant metastasis occurring at first diagnosis. The study was approved by the Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong university.
Clinicopathological data. Clinicopathological data were collected after obtaining informed consent from patients. Pathological examinations, including detection of ER, progesterone receptor (PR), HER2, nuclear protein Ki67, tumor protein p53 and cytokeratin 5/6 (CK5/6) protein expressions by immunohistochemistry (IHC), were conducted in the pathology department of The First Affiliated Hospital of Xi'an Jiaotong University (Xi'an, China (20) (21) (22) (23) (24) (25) . Gene expression did not translate or equate to protein expression of those markers by IHC due to differences in the detection methods. The expression levels of the following 21 gene mRNAs, which are related to recurrence risk, were detected and calculated to determine the RS: Ki67, aurora kinase A (STK15), Survivin, cyclin B1 (CCNB1), MYB proto-oncogene like 2 (MYBL2), growth factor receptor-bound protein 7 (GRB7), HER2, ER, PR, BCL2 apoptosis regulator (BCL2), signal peptide, CuB domain and EGF-like domain-containing 2 (SCUBE2), matrix metallopeptidase 11 (MMP11), cathepsin V (CTSL2), glutathione S-transferase µ1 (GSTM1), scavenger receptor class D, member 1 (CD68), BCL2-associated athanogene 1 (BAG1), β-actin (ACTB), GAPDH, ribosomal protein lateral stalk subunit P0 (RPLP0), β-glucuronidase (GUS) and transferrin receptor (TFRC). RS <18 was categorized as low risk, RS between 18 and 30 was considered to be intermediate risk, and RS ≥31 was categorized as high risk (8) .
Kaplan-Meier Plotter database. As a tool for meta-analysis-based biomarker assessment, the Kaplan-Meier Plotter (http://www.kmplot.com) (26) Statistical analysis. All categorical variables are expressed as the means of absolute numbers and percentages, whereas abnormally distributed continuous variables are expressed as medians and ranges. The associations between the 21-gene RS and clinicopathological characteristics that were categorical variables were analyzed by the χ 2 test. Fisher's exact test was applied when the theoretical frequency was <5 or the total observation frequency was <20. For continuous variables, if they met the assumptions of normality and homogeneity, Student's unpaired t-test was performed. Otherwise, these variables were analyzed by the Wilcoxon rank-sum test. The relationships between the 21-gene RS and chemotherapeutic efficacy-related target genes were estimated using the Wilcoxon rank-sum test, and correlations were tested using Spearman's rank test. Univariate binary logistic regression of clinicopathological characteristics and chemotherapeutic efficacy-related target genes with 21-gene RSs and multivariate logistic analysis of independent variables associated with the 21-gene RS were analyzed. Furthermore, the McNemar χ 2 test was used to compare the differences in treatment decisions before and after the 21-gene test. All statistical tests were two sided. P<0.05 was considered to indicate a statistically significant difference. All analyses were performed using SPSS 18.0 (SPSS, Inc., Chicago, IL, uSA).
Results
Patient clinicopathological characteristics. A total of 110 female patients with ER
+ breast cancer who were tested with the 21-gene RS test and treated at The First Affiliated Hospital of Xi'an Jiaotong University were included in the present study ( Fig. 1 ; Table I ). Based on RS criteria, the majority of patients (59.1%; 65/110) were classified in the low-RS group, 34.5% (38/110) in the intermediate-RS group and 6.4% (7/110) in the high-RS group. Most patients (30.9%; 34/110) were skilled workers. Nearly 96% of patients were married, and the majority (60%; 66/110) had normal BMI. The proportions of postmenopausal and premenopausal patients were 51% (56/110) and 48% (53/110), respectively. A total of 93 (84.6%) patients had invasive ductal carcinoma; none of the patients had lymph node metastasis or a vascular tumor embolus. The clinical stages were I-II (100%). The baseline data are presented in Table I .
Distribution of RS based on clinicopathological characteristics.
The associations between the 21-gene RS and clinicopathological characteristics are shown in Tables II and III . Median age at initial diagnosis of breast cancer in the low-RS group was 52 years old (range, 25-73), whereas median age was 50 years (range, 30-70) in the intermediate/high-RS group. The distribution of the 21-gene RS varied significantly according to BMI, pathological type, histological grade and molecular grade (P<0.05; Table II ). Patients with higher BMI, invasive ductal carcinoma type, higher histological grade and luminal B molecular type were more likely to have higher RS compared with patients with lower BMI, non-invasive ductal carcinoma, lower histological grade and luminal A molecular type (Fig. 2) . In histological grade I-II tumors, the proportions of low and intermediate/high RS were 67.1 and 32.9%, respectively, whereas in patients with histological grade III tumors, the proportions were 39.3 and 60.7% respectively (P=0.010; Fig. 2C ). Similarly, compared with patients with lower BMI, non-invasive ductal carcinoma type and luminal A molecular type, patients with higher BMI, invasive ductal carcinoma type and luminal B molecular type were more likely to be categorized as the intermediate/high-RS group and less likely to be categorized as the low-RS group (P<0.05; Table II 
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Correlation between RS and chemotherapeutic efficacy-related target genes.
The correlation between TYMS gene expression and the RS value was determined to be statistically significant (r= 0.366; P<0.001; Fig. 3A ). Similar level of RRM1 gene expression was noted in both risk groups (Table IV) and no correlation was noted between RRM1 gene expression and the RS value (P=0.592; Fig. 3B ). Although significantly higher TUBB3 gene expression was observed in the intermediate/high-risk RS group, the absolute difference between the two risk groups was not clinically significant and had no correlation (P=0.052; Fig. 3C ). The correlation between TOP2A gene expression and the RS value was statistically significant (r= 0.384; P<0.001; Fig. 3D ). Higher PTEN gene expression was observed in the low-risk RS group, but there was no correlation (P=0.090; Fig. 3E ).
Prognostic values of the mRNA expression levels of chemotherapeutic efficacy-related target genes in ER + breast cancer.
Based on the correlations between RS and several of the tested chemotherapeutic efficacy-related target genes, the prognostic value of the mRNA expression levels of the five chemotherapeutic efficacy-related target genes in 2,061 patients with ER + breast cancer was examined using a Kaplan-Meier plotter database. Among these genes, three were associated with relapse-free survival (RFS) for ER + breast cancer ( Fig. 4A-E Table IV . Relationship between 21-gene RS and chemotherapeutic efficacy-related target genes. 
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Discussion
In the present study, DNA liquid chip technology was used to detect 21-gene RS and the expression profiles of chemotherapeutic efficacy-related target genes as gene expression did not translate or equate to protein expression of those markers identified by IHC. This technology detected >30 genes simultaneously without reverse transcription and polymerase chain reaction. Therefore, the present study reflected the real-life associations between RS and clinicopathological characteristics of breast cancer with more clarity compared with previous studies. As the DNA liquid chip technology had the advantages of parallel detection, high sensitivity, simple operation and a wide linear range, it was suitable for a number of types of samples. In addition, it did not require RNA extraction, reverse transcription and PCR, which reduced the multi-step error accumulation on the results. In addition to the correlation between RS and clinicopathological characteristics, chemotherapeutic efficacy-related target genes were also included in the study. In the present study, 59.1% of the patients were classified as the low-risk RS group, which suggested that chemotherapy may not have been beneficial to at least 59.1% of patients examined between 2013 and 2016. Therefore, in clinical practice, <50% of the patients may have been overtreated with chemotherapy following surgery, resulting not only in adverse reactions, but also increasing medical costs. Furthermore, the present study also indicated that patients with higher BMI, invasive ductal carcinoma type, higher histological grade and luminal B molecular type were more likely to have higher RS. Similarly, the National Surgical Adjuvant Breast and Bowel Project B20 trial also found that patients with histological grade 3, T stage 2-3 and PR-negative tumors were more likely to be categorized as high-risk groups (14) . Correlations between low RS and non-invasive ductal carcinoma type have also been reported (16) . Owing to the cost of 21-gene detection, the assay (27) ; the results revealed that grade and progesterone receptor status were the highest predictors of both low-risk and high-risk RS, followed by age, tumor size, histologic tumor type and lymph-vascular invasion (27) . The aforementioned study reported with confidence that clinicopathological variables may be used for prediction of low-risk or high-risk RS using nomogram models, which may help physicians and patients decide whether further 21-gene RS test is necessary and function as surrogates for patients for whom 21-gene RS test is not affordable or unavailable (27) . Multivariate analysis in the present study demonstrated that BMI, histological grade and TOP2A were independent variables associated with RS. These results suggested that the 21-gene RS effectively integrated clinicopathological features and provided further information regarding breast cancer. The correlations reported in the present study indicated that traditional routine clinicopathological characteristics may aid in the prediction of RS.
There were certain discrepancies between RS and clinicopathological characteristics. A number of patients with risk factors for recurrence demonstrated low RS. For example, 24.6% (16/65) of patients with higher BMI (≥24) had RS <18. In addition, 17.7% (11/62) of patients with histological grade III tumors were categorized in the low-risk RS group. Therefore, the use of one or several clinicopathological characteristics to predict RS score may not be accurate; however, 21-gene test may help avoid these deviations and may be more comprehensive. These differences between RS and clinicopathological characteristics demonstrated that the 21-gene RS may provide more accurate and verifiable prognostic information compared with traditional clinicopathological characteristics.
A retrospective study by Stemmer et al demonstrated that in patients with ER + breast cancer with up to three positive nodes, including micrometastases, tested using the Oncotype DX gene test, the chemotherapy use was lower compared with untested patients (24.5 vs. 70.1%), which suggested that Oncotype DX testing has a significant impact on reducing chemotherapy use (28) . A retrospective analysis of a prospective designed registry, which included 1,801 patients with ER + /HER2 -, lymph node-negative breast cancer (median follow-up, 6.2 years), demonstrated that estimates for distant recurrence and breast cancer mortality rate for the RS <18 patients were very low, supporting the use of endocrine therapy alone (29) . Additional findings from another study supported the use endocrine therapy alone in patients with ER + /HER2 -breast cancer with micrometastases, 1-3 positive nodes and recurrence score <18 (30) . When patients with RS 11-25 were randomized to receive either chemotherapy or endocrine therapy, the results revealed that chemotherapy was not more effective compared with endocrine therapy (29 (32) . These data demonstrated that RS test may be essential to avoid unnecessary chemotherapy. Similarly, the present study revealed that for patients with hormone receptor-positive and lymph node-negative early-stage breast cancer, 21-gene RS test may aid to avoid excessive postoperative adjuvant chemotherapy and lessen the side effects of chemotherapy. The change rate of treatment decision before and after 21-gene RS detection in China is in the top 8 in the world (uK 10%, Italy 12%, uSA 22%, Japan 26%, China 29%, Germany 30%, Spain 33% and South Korea 51%) (31) (32) (33) (34) (35) (36) (37) .
Notably, the distribution of RS according to chemotherapeutic efficacy-related target genes was analyzed. The detection of PTEN and other chemotherapeutic efficacy-related target genes has been previously used to predict the curative effect of target drugs and to inform their use to help patients select appropriate chemotherapy drugs (21) (22) (23) (24) (25) . However, the data revealed that the proportion of intermediate/high-risk RS was significantly higher among patients with higher TYMS and TOP2A expression. TYMS and TOP2A gene expression correlated with the RS value, which suggested that TYMS and TOP2A gene expression may also predict prognosis and recurrence risk in patients with breast cancer. As the sample size of the present study was small, these distinct gene expression profiles were further tested in Kaplan-Meier for survival analysis. The data (n=2,061) demonstrated that TYMS, TUBB3 and TOP2A gene expression levels were significantly associated with RFS for ER + breast cancer. These results suggested that there may be more meaningful tumor-related genes that may be used in RS classification and that the criteria for RS categories may be worth reviewing.
The 21-gene RS test were mainly applied in patients with ER + /HER2 -, lymph node metastasis-negative breast cancer. In the future, the scope of application may be expanded to include patients with lymph node metastasis into the analysis to explore the value of the RS assay in these populations.
The 21-gene RS correlated significantly with BMI, pathological type, histological grade, molecular grade and several chemotherapeutic efficacy-related target genes, including TYMS and TOP2A. These results may be used to provide more information compared with clinicopathological indexes and inform treatment plans. The 21-gene RS test may help avoid excessive postoperative adjuvant chemotherapy. Large amounts of data in the Kaplan-Meier plotter database demonstrated that TYMS, TUBB3 and TOP2A gene expression levels were significantly associated with RFS for ER + breast cancer. Therefore, TYMS, TUBB3 and TOP2A gene expression levels may have prognostic value for ER + breast cancer.
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